Neurocrine Biosciences | NBIX - Cost Of Sales


Neurocrine Biosciences reported $39.4M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
Exelixis USD 20.66M 704K Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Repligen USD 94.09M 8.12M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Teva Pharmaceutical Industries USD 1.98B 30M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026